Literature DB >> 29234641

ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function.

Atsushi Hiraoka1, Kojiro Michitaka1, Takashi Kumada2, Masashi Kudo3.   

Abstract

Entities:  

Year:  2017        PMID： 29234641      PMCID： PMC5704723          DOI： 10.1159/000481212

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  4 in total

1.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

2.  ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yun-Hsuan Lee; Yi-You Chiou; Yi-Hsiang Huang; Fa-Yauh Lee; Han-Chieh Lin; Ming-Chih Hou; Teh-Ia Huo
Journal:  J Gastroenterol Hepatol       Date:  2017-04       Impact factor: 4.029

3.  Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Hidenori Toyoda; Toshifumi Tada; Hidetaro Ueki; Miho Kaneto; Toshihiko Aibiki; Tomonari Okudaira; Takamasa Kawakami; Tomoe Kawamura; Hiroka Yamago; Yoshifumi Suga; Yuji Miyamoto; Hideomi Tomida; Nobuaki Azemoto; Kenichiro Mori; Hideki Miyata; Tomoyuki Ninomiya; Hideki Kawasaki
Journal:  J Gastroenterol Hepatol       Date:  2016-05       Impact factor: 4.029

4.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-09-22       Impact factor: 11.740
  4 in total
  10 in total

1.  Laparoscopic versus open mesohepatectomy for patients with centrally located hepatocellular carcinoma: a propensity score matched analysis.

Authors:  Wei Li; Jun Han; Guowei Xie; Yang Xiao; Ke Sun; Kefei Yuan; Hong Wu
Journal:  Surg Endosc       Date:  2018-11-29       Impact factor: 4.584

2.  An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study.

Authors:  Ming-Hao Xu; Bin Xu; Chen-Hao Zhou; Zhong Xue; Zhao-Shuo Chen; Wen-Xin Xu; Cheng Huang; Xiao-Dong Zhu; Jian Zhou; Jia Fan; Hui-Chuan Sun; Ying-Hao Shen
Journal:  World J Surg Oncol       Date:  2022-06-16       Impact factor: 3.253

3.  Predicting the survival rate of patients with hepatocellular carcinoma after thermal ablation by nomograms.

Authors:  Yan Zhou; Jianmin Ding; Zhengyi Qin; Yijun Wang; Jiayi Zhang; Kefeng Jia; Yandong Wang; Hongyu Zhou; Fengmei Wang; Xiang Jing
Journal:  Ann Transl Med       Date:  2020-09

4.  Preoperative Albumin-Bilirubin Grade as a Prognostic Predictor in Colorectal Cancer Patients Who Undergo Radical Resection.

Authors:  Ce Zhu; Xiang Wang; Xinxin Yang; Jing Sun; Bujian Pan; Weiteng Zhang; Xiaodong Chen; Xian Shen
Journal:  Cancer Manag Res       Date:  2020-12-01       Impact factor: 3.989

5.  Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kunihiko Tsuji; Koichi Takaguchi; Ei Itobayashi; Kazuya Kariyama; Hironori Ochi; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Toru Ishikawa; Yoshihiko Tachi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-06-11       Impact factor: 11.740

6.  KIFC1 promotes the proliferation of hepatocellular carcinoma in vitro and in vivo.

Authors:  Xing Wang; Meng Wang; Xing-Yue Li; Jian Li; Dian-Peng Zhao
Journal:  Oncol Lett       Date:  2019-10-14       Impact factor: 2.967

7.  Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation.

Authors:  Chao An; Xin Li; Xiaoling Yu; Zhigang Cheng; Zhiyu Han; Fangyi Liu; Jie Yu; Ping Liang
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

8.  Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience.

Authors:  Ouissam Al Jarroudi; Hamed Chaabouni; Ayhan Ulusakarya; Wathek Almohamad; Yusuf Gumus; Emma Goldschmidt; Said Afqir; Jean-Francois Morère
Journal:  Clin Case Rep       Date:  2021-02-20

9.  Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.

Authors:  Hideto Kawaratani; Yasuteru Kondo; Ryoji Tatsumi; Naoto Kawabe; Norikazu Tanabe; Akira Sakamaki; Kazuo Okumoto; Yoshihito Uchida; Kei Endo; Takumi Kawaguchi; Tsunekazu Oikawa; Yoji Ishizu; Shuhei Hige; Taro Takami; Shuji Terai; Yoshiyuki Ueno; Satoshi Mochida; Yasuhiro Takikawa; Takuji Torimura; Tomokazu Matsuura; Masatoshi Ishigami; Kazuhiko Koike; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2022-03-12       Impact factor: 4.241

10.  MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation.

Authors:  Ayman Alsebaey; Aliaa Sabry; Hanaa Said Rashed; Maha Mohammad Elsabaawy; Amr Ragab; Rasha Abdelhafiz Aly; Hanaa Badran
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.